PLAUR, C3, and EMP3 coordinate tumor progression and immune evasion in clear cell renal cell carcinoma Authors: S. R. Zi, Z. Y. Feng, L. S. Dong Published: 2025 ABSTRACT BackgroundClear cell renal cell carcinoma (ccRCC) progression is closely associated with the tumor microenvironment and immune evasion mechanisms. Identifying key molecular drivers is critical for advancing ccRCC diagnosis and therapy.MethodsDifferentially expressed genes (DEGs) were identified through analysis of the GSE6344 and GSE781 datasets. Weighted Gene Co-expression Network Analysis (WGCNA) was performed to uncover co-expression modules that exhibit significant correlation with clinical traits. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses, coupled with survival analysis, were employed to pinpoint potential hub genes. Single-cell RNA-seq data were analyzed to clarify cellular sources of PLAUR, C3, and EMP3. Functional validation of these genes was conducted using a range of assays, including RT-qPCR, Western blotting, CCK-8, wound healing, Transwell, and ELISA in both normal kidney cells and ccRCC cell lines.ResultsPLAUR, C3, and EMP3 were identified as hub genes enriched in extracellular matrix and immune-related pathways. All three genes were found to be overexpressed in ccRCC and associated with poor prognosis. Single-cell RNA-seq analysis revealed that PLAUR and C3 are primarily expressed in immune cells with detectable levels in tumor epithelial cells, whereas EMP3 exhibits a broader distribution, including strong expression in tumor epithelial cells. Silencing of PLAUR, C3, or EMP3 resulted in a marked inhibition of tumor proliferation, migration, and invasion. Notably, PLAUR knockdown exhibited the most substantial effect, disrupting immune evasion by reducing the levels of TGF-β, IL-10, and IL-6, while increasing the levels of IFN-γ, IL-2, and TNF-α in ccRCC cells co-cultured with T-cells.ConclusionsPLAUR, C3, and EMP3 promote ccRCC progression and immune evasion, with PLAUR acting as the dominant driver. Targeting PLAUR may provide a promising strategy to enhance anti-tumor immunity in ccRCC.Graphical Abstract Supplementary InformationThe online version contains supplementary material available at 10.1007/s12672-025-04292-3. Introduction Among the various subtypes of renal cell carcinoma, clear cell renal cell carcinoma (ccRCC) is the most frequently diagnosed and presenting with distinct pathological and clinical features [37]. Despite advancements in diagnostic and therapeutic strategies, ccRCC remains a highly aggressive cancer with poor prognosis, particularly in cases of advanced disease [6, 29]. The complex interplay between tumor cells and the tumor microenvironment (TME) significantly influences ccRCC progression, therapy resistance, and immune evasion [32]. Elucidating the molecular drivers within this landscape is therefore crucial for identifying novel diagnostic biomarkers and therapeutic targets. A hallmark of ccRCC is its altered gene expression profile, which reflects its reliance on dysregulated cellular pathways, such as extracellular matrix (ECM) remodeling, metabolic reprogramming, and immune modulation [25, 40]. Studies highlighted the pivotal roles of these pathways in fostering tumor growth and immune escape. In particular, ECM dynamics and immune-related pathways are known to create a supportive niche for tumor proliferation and metastasis while suppressing anti-tumor immune responses [23]. However, the molecular regulators mediating these processes in ccRCC remain incompletely understood. Bioinformatics approaches have proven invaluable in uncovering key genes and pathways implicated in cancer progression. Weighted Gene Co-expression Network Analysis (WGCNA) facilitates the discovery of gene modules linked to clinical characteristics, providing valuable insights into the molecular mechanisms underlying cancer [14]. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) further aid in characterizing the biological roles of hub genes [28, 39]. These computational methods, combined with experimental validation, provide a comprehensive framework for understanding tumor biology and immune evasion. In this study, we combined bioinformatics and experimental approaches to identify and validate key molecular drivers of ccRCC progression and immune regulation. Utilizing publicly available gene expression datasets, we detected differentially expressed genes (DEGs) and clinically relevant co-expression networks. Functional enrichment analyses highlighted critical pathways and biological processes underlying ccRCC progression. Prognostic evaluation identified genes associated with patient outcomes, leading to the prioritization of key hub genes, including PLAUR, C3, and EMP3. Experimental validation further demonstrated their significant roles in tumor proliferation and immune evasion. This study provides valuable insights into the molecular mechanisms driving ccRCC progression and immune modulation, offering potential avenues for the development of novel diagnostic biomarkers and targeted therapies to improve patient outcomes. Materials and methods Study design and data acquisition By combining bioinformatics analysis with experimental validation, this study uncovered potential therapeutic targets associated with tumor progression and immune modulation. Gene expression datasets GSE6344 and GSE781 were retrieved from the Gene Expression Omnibus (GEO) database, encompassing ccRCC and normal kidney samples. All bioinformatics analyses were conducted using the Sangerbox platform [2] (http://sangerbox.com). DEGs were identified from the GSE6344 and GSE781 datasets, followed by WGCNA to identify clinically relevant co-expression modules. Functional and pathway enrichment analyses were performed to elucidate the biological significance of these modules. Hub genes were prioritized based on survival analysis and correlation studies and subsequently validated experimentally. To clarify their cellular sources within the tumor microenvironment, single-cell RNA-seq data from the Human Cell Atlas (https://explore.data.humancellatlas.org/projects/ee166275-f63a-4864-8155-4df86c9de679; patient_2_ccRCC) were analyzed using Seurat (v4, R 4.3) and SingleR, and the expression of PLAUR, C3, and EMP3 was visualized across annotated cell populations. Gene expression was assessed in various cell lines via RT-qPCR and Western blotting. Functional assays, including proliferation, migration, invasion, and immune response evaluations, were utilized to determine the influence of gene knockdown on tumor cells. Differential expression analysis The Limma package in R was used to identify DEGs in the GSE6344 and GSE781 datasets. DEGs were determined based on adjusted P-value < 0.05 and fold change (FC) > 1.5. Venn diagram analysis was performed to identify overlapping DEGs consistently dysregulated across both datasets. WGCNA analysis To identify gene modules associated with ccRCC clinical traits, WGCNA was performed on the GSE781 dataset. The optimal soft-thresholding power (β) was selected to establish a scale-free network structure with R² exceeding 0.85. Modules were identified via hierarchical clustering and dynamic tree cutting, and their correlations with clinical traits were assessed using module eigengene analysis. Functional and pathway enrichment analysis GO and KEGG annotations were performed using the org.Hs.eg.db package in R, mapping genes to the reference dataset. The clusterProfiler package was utilized to conduct enrichment analysis, identifying significantly enriched GO terms and KEGG pathways. The parameters were configured with a gene set size ranging from a minimum of 5 to a maximum of 5000. Enriched terms were considered statistically significant with a P-value < 0.05 and a false discovery rate (FDR) < 0.1 (Benjamini & Hochberg). Survival analysis Kaplan-Meier survival analysis was conducted using the GEPIA2 platform to assess their prognostic relevance. Hub genes with significant associations with overall survival (P < 0.05) were prioritized for experimental validation. Single-cell RNA-seq analysis Single-cell transcriptomic data for ccRCC were obtained from the Human Cell Atlas Data Portal (https://explore.data.humancellatlas.org/projects/ee166275-f63a-4864-8155-4df86c9de679), specifically using the patient_2_ccRCC sample. Raw count matrices (10x Genomics format) were processed with Seurat (v4, R 4.3). Low-quality cells were removed if nFeature_RNA < 200, nFeature_RNA > 6,000, or percent.mt ≥ 10%. Data were log-normalized, variable features were identified, and scaling was applied. Dimensionality reduction was performed by PCA (top 20 PCs), followed by graph-based clustering at resolution = 0.5 and visualization with UMAP and t-SNE. Cluster marker genes were identified using the Wilcoxon rank-sum test (min.pct = 0.25, logFC > 0.25) and summarized with heatmaps. Cell-type annotation was conducted using SingleR with the Human Primary Cell Atlas reference. Expression distributions of PLAUR, C3, and EMP3 were assessed by FeaturePlot and violin plots across annotated cell types. Cell culture and transfection Normal kidney epithelial cells (HK-2), human ccRCC cell lines (A498, Caki-1, 786-O), and their respective specialized culture medium were obtained from Wuhan Pricella Biotechnology Co., Ltd. Cells were cultured in their designated medium (CM-0254, CM-0052, CM-0326, CM-0010, CM-0109) and maintained at 37 °C in a humidified atmosphere with 5% CO₂. For gene knockdown, shRNAs targeting PLAUR (GCCGTTACCTCGAATGCATTTCTCGAGAAATGCATTCGAGGTAACGGC), C3 (GCCAGGAGTAACCTGGATGAGGACATCATTGCAGAAGAGAA), and EMP3 (TGGTCTCAGCCCTTCACATCCTCATTCTTATACTGCTTTTC) were cloned into pLKO.1 vectors, with non-targeting shRNA (CCTAAGGTTAAGTCGCCCTCG) as a control. HEK293T cells were co-transfected with shRNA plasmids and packaging vectors (psPAX2, pMD2.G) using Lipofectamine 3000 (Thermo Fisher Scientific) to generate lentiviral particles. Purified viral supernatants were used to infect ccRCC cells in the presence of 8 µg/mL polybrene. Stable knockdown cell lines were selected using 2 µg/mL puromycin, and knockdown efficiency was confirmed via RT-qPCR. RNA extraction and quantitative real-time PCR (RT-qPCR) Total RNA was extracted using TRIzol reagent (Invitrogen, 15596018CN), and cDNA synthesis was performed using a reverse transcription kit (Roche, 11855476001). RT-qPCR was conducted to quantify mRNA levels of PLAUR, C3, EMP3, and GAPDH. Relative expression was calculated using the 2^-ΔΔCt method. Primer sequences used for RT-qPCR analysis were listed in Table 1. Table 1Primer sequences used for RT-qPCR analysisGenesForward SequenceReverse SequencePLAURCCACTCAGAGAAGACCAACAGGGTAACGGCTTCGGGAATAGGTGC3GTGGAAATCCGAGCCGTTCTCTGATGGTTACGGTCTGCTGGTGAEMP3TGTTCCAGCTCTACACCATGCGATCTCCTCGGCGTGAATGGCATGAPDHGTCTCCTCTGACTTCAACAGCGACCACCCTGTTGCTGTAGCCAA Table 1Primer sequences used for RT-qPCR analysisGenesForward SequenceReverse SequencePLAURCCACTCAGAGAAGACCAACAGGGTAACGGCTTCGGGAATAGGTGC3GTGGAAATCCGAGCCGTTCTCTGATGGTTACGGTCTGCTGGTGAEMP3TGTTCCAGCTCTACACCATGCGATCTCCTCGGCGTGAATGGCATGAPDHGTCTCCTCTGACTTCAACAGCGACCACCCTGTTGCTGTAGCCAA Primer sequences used for RT-qPCR analysis Western blot analysis Protein lysates were equally loaded, separated via SDS-PAGE, and transferred onto PVDF membranes (Thermo Fisher Scientific, 88518). The membranes were incubated overnight at 4 °C with primary antibodies, including PLAUR (Proteintech, 10286-1-AP, 1:1500), C3 (Abcam, Ab97462, 1:1500), EMP3 (Affinity, DF14661, 1:500), and β-actin (Proteintech, 60008-1-Ig, 1:5000) as the loading control. After incubation with appropriate HRP-conjugated secondary antibodies, protein bands were visualized using enhanced chemiluminescence detection. Quantitative analysis of band intensities was performed using ImageJ software. CCK-8 assay In 96-well plates, transfected ccRCC cells were seeded at a density of 2 × 10⁴ cells per well in 100 µL of complete medium and maintained at 37 °C with 5% CO₂. CCK-8 reagent (10 µL; Beyotime Biotechnology, #C0038) was added to each well at 0, 12, and 24 h, followed by a 2-hour incubation. Absorbance at 450 nm was measured using a BioTek Synergy HTX microplate reader. CCK-8 assays were performed in triplicate and repeated independently three times. Data were analyzed using two-way repeated measures ANOVA (factors: time and treatment group), followed by Dunnett’s multiple comparisons test to compare each knockdown group with the shNC control. Statistical analyses were performed with GraphPad Prism 9.0, and P < 0.05 was considered statistically significant. Wound healing assay Transfected cells were plated in 6-well plates and allowed to grow to 90% confluency for the wound healing assay. A sterile 200 µL pipette tip was used to create a scratch, followed by PBS washing to remove cell debris. Fresh serum-free medium was then added, and images of the wound area were taken at 0 and 24 h using an Olympus IX73 inverted microscope. Scratch closure was quantified using ImageJ software. Invasion assay For the invasion assay, 24-well Transwell chambers with 8 μm pore membranes (Corning, #3422) were coated with Matrigel (BD Biosciences, #356234). Transfected cells (2 × 10⁴ cells/well) were suspended in 200 µL serum-free medium and seeded into the upper chambers. The lower chambers were filled with 600 µL of medium containing 10% FBS as a chemoattractant. After 24 h of incubation at 37 °C, non-invading cells were removed from the upper surface, and invading cells on the lower surface were fixed with 4% paraformaldehyde, stained with 0.1% crystal violet, and counted under a microscope. Tumor-T cell co-culture and cytokine analysis Caki-1 cells transfected with shRNA constructs targeting PLAUR, C3, or EMP3, or negative control (shNC), were seeded into the lower chambers of 24-well Transwell plates (Corning, #3413) at a density of 1 × 10⁵ cells/well in 500 µL of RPMI-1640 medium supplemented with 10% FBS. Activated T cells were prepared by stimulating primary human peripheral blood mononuclear cells (PBMCs) with anti-CD3/CD28 beads (Thermo Fisher Scientific, #11131D) at a bead-to-cell ratio of 1:1 in RPMI-1640 medium containing 10% FBS for 24 h. Activated T cells were then seeded into the upper chambers with 0.4 μm pores. Co-culture was maintained at 37 °C with 5% CO₂ for 48 h. Following co-culture, supernatants were collected for cytokine analysis, and tumor cell viability was assessed. Cytokine concentrations, including TGF-β, IL-10, IL-6, IFN-γ, IL-2, and TNF-α, were measured using ELISA kits (Thermo Fisher Scientific, #88-8350-88, #88-7106-88, #88-7066-88, #88-7316-86, #88-7025-88, and #88-7346-86, respectively) according to the manufacturer’s instructions. Absorbance was measured at 450 nm using a microplate reader. To evaluate the viability of tumor cells post-co-culture, the CCK-8 assay was performed as previously described. Statistical analysis Data analysis was conducted using GraphPad Prism 9.0. Group comparisons were performed using one-way ANOVA or Student’s t-test. Results are expressed as mean ± standard deviation (SD), with statistical significance set at P < 0.05. Results DEGs in CcRCC tumor and normal samples The limma package was utilized to analyze two GEO datasets, GSE6344 (n = 20) and GSE781 (n = 17), to identify significant differences in gene expression. In GSE6344, 1873 upregulated and 2399 downregulated genes were identified, while GSE781 yielded 1017 upregulated and 768 downregulated genes under the same criteria (P < 0.05, FC > 1.5). Given the limited number of statistically significant genes at FDR < 0.05 in GSE781, a consistent threshold of P < 0.05 was applied to both datasets for comparative purposes. The results are visually summarized in Fig. 1. Volcano plots (Fig. 1A) illustrate the distribution of upregulated and downregulated genes, while heatmaps (Fig. 1B) highlight clear clustering and distinct expression profiles between tumor and normal samples, focusing on the top 10 genes. To identify genes consistently dysregulated across datasets, a Venn diagram analysis was conducted (Fig. 1C), revealing 658 consistently upregulated and 653 consistently downregulated genes between GSE6344 and GSE781. These overlapping DEGs represent a robust set of candidate genes, forming a solid foundation for further functional validation and mechanistic studies in RCC research. Fig. 1DEGs in ccRCC tumor and normal samples. (A) Volcano plots showed the distribution of significantly upregulated (red) and downregulated (green) genes in GSE6344 and GSE781 datasets. (B) Heatmaps illustrated distinct expression patterns and clustering of DEGs between tumor and normal samples, with red and blue indicating higher and lower expression levels, respectively. (C) Venn diagrams highlighted 658 overlapping upregulated genes and 653 overlapping downregulated genes identified across both datasets. DEGs in ccRCC tumor and normal samples. (A) Volcano plots showed the distribution of significantly upregulated (red) and downregulated (green) genes in GSE6344 and GSE781 datasets. (B) Heatmaps illustrated distinct expression patterns and clustering of DEGs between tumor and normal samples, with red and blue indicating higher and lower expression levels, respectively. (C) Venn diagrams highlighted 658 overlapping upregulated genes and 653 overlapping downregulated genes identified across both datasets. Identification of hub genes associated with CcRCC clinical traits Due to limited clinical information in the GSE6344 dataset, WGCNA was performed on GSE781 to identify clinically relevant gene modules. At β = 4, the network achieved an R² of 0.89 and a mean connectivity of 314.10 (Fig. 2A). Hierarchical clustering identified distinct co-expression modules, with the blue, dark magenta, pink, light cyan 1, sienna 3, and sky blue modules significantly associated with ccRCC clinical traits (Fig. 2B-D). For example, the blue module exhibited negative correlations with tumor grade (P < 0.05) and perinephric fat invasion (P < 0.001), while the pink and dark magenta modules showed positive correlations with tumor grade (P < 0.05) and perinephric fat invasion (P < 0.01). Additionally, the light cyan 1 module was positively correlated with patient age (P < 0.05). Hub genes were identified using a module membership threshold of 0.8. Venn diagram analysis revealed 5, 8, and 29 overlapping genes from the blue, dark magenta, and pink modules that were consistently up-regulated in both datasets (Fig. 2E), representing key candidates for further study. Fig. 2DEGs in tumor and normal samples. (A) Determination of soft-thresholding power (β) for constructing a scale-free network. (B) Gene dendrogram and module identification using hierarchical clustering and dynamic tree cutting. (C) Heatmap showing correlations among module eigengenes. (D) Heatmap illustrating module-trait relationships. (E) Venn diagrams of overlapping genes between selected modules and consistently regulated genes. DEGs in tumor and normal samples. (A) Determination of soft-thresholding power (β) for constructing a scale-free network. (B) Gene dendrogram and module identification using hierarchical clustering and dynamic tree cutting. (C) Heatmap showing correlations among module eigengenes. (D) Heatmap illustrating module-trait relationships. (E) Venn diagrams of overlapping genes between selected modules and consistently regulated genes. Functional and pathway enrichment analysis of hub DEGs and their prognostic implications The identified hub genes from the blue, dark magenta, and pink modules underwent GO and KEGG enrichment analysis. 4 out of 5 genes in the blue module were enriched in terms related to extracellular matrix (ECM) dynamics, tumor progression, and microenvironment remodeling (Fig. 3A, left). For the dark magenta module, 7 out of 8 genes were enriched in GO terms associated with intracellular signaling, protein processing and transport, cellular communication, and homeostasis (Fig. 3A, middle). Similarly, 23 out of 29 genes in the pink module were enriched in GO terms linked to protein modification processes, extracellular region functions, and endomembrane system activities (Fig. 3A, right). KEGG enrichment analysis revealed no pathways for the blue module. However, 5 out of 8 genes in the dark magenta module were enriched in pathways related to cellular proliferation, communication, and hormonal regulation (Fig. 3B, left), emphasizing their roles in. In the pink module, 7 out of 29 genes were enriched in KEGG pathways linked to metabolic regulation, immune response, and protein synthesis (Fig. 3B, right). To pinpoint the most valuable genes in ccRCC, we further focused on the 4 genes in the blue module enriched in GO analysis, along with the overlapping 5 and 7 genes from the dark magenta and pink modules identified through GO and KEGG analysis (Fig. 3C). Survival analysis was performed using GEPIA 2, including survival heatmaps and individual gene overall survival analysis in RCC. The analysis revealed (Fig. 3D) that elevated expression of PLAUR, C3, and EMP3 (pink module) was significantly correlated with poor overall survival (P < 0.05), whereas reduced expression of SLC38A1 (blue module) was associated with unfavorable survival outcomes (P < 0.05). Given that all four genes analyzed (PLAUR, C3, EMP3, and SLC38A1) are upregulated in tumor tissues, we ultimately prioritized PLAUR, C3, and EMP3 genes for further investigation. Fig. 3Functional and pathway enrichment analysis of hub DEGs and their prognostic implications. (A) GO enrichment analysis of hub genes from the blue, dark magenta, and pink modules. (B) KEGG pathway enrichment analysis for hub genes in the dark magenta and pink modules. (C) Venn diagram showing overlapping genes across the blue, dark magenta, and pink modules. (D) Survival analysis of selected hub genes, including a survival heatmap and Kaplan-Meier survival curves for EMP3, SLC38A1, C3 and PLAUR. Functional and pathway enrichment analysis of hub DEGs and their prognostic implications. (A) GO enrichment analysis of hub genes from the blue, dark magenta, and pink modules. (B) KEGG pathway enrichment analysis for hub genes in the dark magenta and pink modules. (C) Venn diagram showing overlapping genes across the blue, dark magenta, and pink modules. (D) Survival analysis of selected hub genes, including a survival heatmap and Kaplan-Meier survival curves for EMP3, SLC38A1, C3 and PLAUR. Single-cell transcriptome analysis of PLAUR, C3, and EMP3 in the tumor microenvironment To further delineate the cellular sources of PLAUR, C3, and EMP3 in the tumor microenvironment, we examined their expression profiles using publicly available single-cell RNA sequencing datasets. As shown in Fig. 4, PLAUR expression was predominantly enriched in dendritic cells, macrophages, monocytes, and NK cells, whereas C3 expression was mainly restricted to monocyte/macrophage populations, consistent with its role as a complement component. In contrast, EMP3 displayed a broader distribution across multiple cell types, including B cells, NK cells, and epithelial-derived populations. These findings highlight the cell-type specific expression patterns of the three hub genes, suggesting that PLAUR and C3 are primarily derived from immune cells within the TME, while EMP3 is widely expressed, including in tumor epithelial cells. This cellular heterogeneity provides important context for our subsequent functional studies in ccRCC cell lines. Fig. 4Single-cell transcriptome analysis of PLAUR, C3, and EMP3 in the tumor microenvironment. (A) Quality control plots showing the distribution of detected genes per cell (nFeature_RNA), total transcript counts per cell (nCount_RNA), and mitochondrial transcript percentage (percent.mt). Cells with < 200 or > 6000 detected genes and ≥ 10% mitochondrial transcripts were excluded from downstream analysis. (B) UMAP projection of single-cell transcriptomes annotated by SingleR using the Human Primary Cell Atlas as reference. Distinct immune and non-immune cell populations are indicated by colors. (C) Feature plots displaying the spatial expression of PLAUR, C3, and EMP3 across single-cell clusters. Color intensity reflects normalized expression levels. (D) Violin plots showing normalized expression levels of PLAUR (red), C3 (green), and EMP3 (blue) across annotated cell types. Single-cell transcriptome analysis of PLAUR, C3, and EMP3 in the tumor microenvironment. (A) Quality control plots showing the distribution of detected genes per cell (nFeature_RNA), total transcript counts per cell (nCount_RNA), and mitochondrial transcript percentage (percent.mt). Cells with < 200 or > 6000 detected genes and ≥ 10% mitochondrial transcripts were excluded from downstream analysis. (B) UMAP projection of single-cell transcriptomes annotated by SingleR using the Human Primary Cell Atlas as reference. Distinct immune and non-immune cell populations are indicated by colors. (C) Feature plots displaying the spatial expression of PLAUR, C3, and EMP3 across single-cell clusters. Color intensity reflects normalized expression levels. (D) Violin plots showing normalized expression levels of PLAUR (red), C3 (green), and EMP3 (blue) across annotated cell types. Upregulation of C3, EMP3, and PLAUR in CcRCC cell lines To investigate their function in tumor cells, we first examined their RNA and protein expression levels across normal kidney and ccRCC cell lines. As shown in Fig. 5A, compared to HK-2, PLAUR, C3, and EMP3 mRNA levels were upregulated in ccRCC cells (P < 0.05). Specifically, PLAUR and C3 exhibited the highest expression in Caki-1, while EMP3 was most elevated in A498. Protein expression analysis (Fig. 5B) showed that consistent with mRNA trends, PLAUR, C3, and EMP3 proteins were markedly higher in ccRCC cell lines (P < 0.05). Notably, C3 was most abundant in Caki-1, while PLAUR and EMP3 showed elevated levels in Caki-1 and 786-O cell lines. These findings indicate that PLAUR, C3, and EMP3 are consistently upregulated at both mRNA and protein levels in ccRCC cell lines, suggesting their potential roles in ccRCC progression and as biomarkers for further investigation. Fig. 5Upregulation of C3, EMP3, and PLAUR in ccRCC cell lines. (A) Relative RNA expression levels of PLAUR, C3, and EMP3 were analyzed via RT-qPCR across normal kidney cells (HK-2) and RCC cell lines (A498, Caki-1, 786-O). (B) Protein expression levels of PLAUR, C3, and EMP3 were examined using Western blot analysis. Data are presented as mean ± SD, and statistical significance is indicated as follows: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; ns = not significant. Upregulation of C3, EMP3, and PLAUR in ccRCC cell lines. (A) Relative RNA expression levels of PLAUR, C3, and EMP3 were analyzed via RT-qPCR across normal kidney cells (HK-2) and RCC cell lines (A498, Caki-1, 786-O). (B) Protein expression levels of PLAUR, C3, and EMP3 were examined using Western blot analysis. Data are presented as mean ± SD, and statistical significance is indicated as follows: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; ns = not significant. Knockdown of PLAUR, C3, and EMP3 inhibits CcRCC cell growth and invasiveness To explore the roles of PLAUR, C3, and EMP3 in ccRCC progression, shRNA-mediated knockdown was performed, and their effects on cell viability, migration, and invasion were evaluated. Knockdown efficiency was confirmed using RT-qPCR, which demonstrated significant reductions in PLAUR, C3, and EMP3 knockdown groups (P < 0.0001, Fig. 6A). CCK-8 assay was conducted at 0, 12, and 24 h post-transfection (Fig. 6B). Knockdown of C3 and EMP3 significantly reduced cell viability at 24 h (P < 0.05), while PLAUR knockdown exhibited a pronounced inhibitory effect as early as 12 h post-transfection (P < 0.05). The wound healing assay revealed that silencing PLAUR, C3, or EMP3 markedly suppressed cell migration (P < 0.05, Fig. 6C). Similarly, Transwell invasion assays demonstrated a significant decrease in invasion following knockdown of PLAUR, C3, or EMP3, with the strongest inhibitory effect noted in the PLAUR knockdown group (P < 0.05, Fig. 6D). These findings demonstrated that PLAUR, C3, and EMP3 are critical for ccRCC cell viability, migration, and invasion, suggesting their potential as therapeutic targets in ccRCC. Fig. 6Knockdown of PLAUR, C3, and EMP3 inhibits ccRCC cell growth and invasiveness. (A) The mRNA expression levels of PLAUR, C3, and EMP3 were quantified using qRT-PCR in Caki-1 cells with PLAUR, C3, or EMP3 knockdown. (B) Cell viability was assessed by CCK-8 assay in Caki-1 cells with PLAUR, C3, or EMP3 knockdown (* shPLAUR vs. shNC; # shC3 vs. shNC; & shEMP3 vs. shNC). (C) Wound healing assay was conducted to evaluate cell migration, with the percentage of wound healing shown in the bar graph on the right. (D) Transwell invasion assay showed the invasive ability of cells, with the number of invaded cells quantified on the right. Data are expressed as mean ± SD, with statistical significance denoted as follows: *P < 0.05, **P < 0.01, ****P < 0.0001; & P < 0.05, ###P < 0.001, ns = not significant. Knockdown of PLAUR, C3, and EMP3 inhibits ccRCC cell growth and invasiveness. (A) The mRNA expression levels of PLAUR, C3, and EMP3 were quantified using qRT-PCR in Caki-1 cells with PLAUR, C3, or EMP3 knockdown. (B) Cell viability was assessed by CCK-8 assay in Caki-1 cells with PLAUR, C3, or EMP3 knockdown (* shPLAUR vs. shNC; # shC3 vs. shNC; & shEMP3 vs. shNC). (C) Wound healing assay was conducted to evaluate cell migration, with the percentage of wound healing shown in the bar graph on the right. (D) Transwell invasion assay showed the invasive ability of cells, with the number of invaded cells quantified on the right. Data are expressed as mean ± SD, with statistical significance denoted as follows: *P < 0.05, **P < 0.01, ****P < 0.0001; & P < 0.05, ###P < 0.001, ns = not significant. PLAUR, C3, and EMP3 were key drivers of immune evasion in CcRCC Given that PLAUR, C3, and EMP3 were functionally enriched in ECM and immune-related pathways, their potential roles in promoting immune evasion in ccRCC were investigated. We then elucidated the roles of these genes in regulating immune microenvironment factors associated with immune evasion. Caki-1 cells with knockdowns of PLAUR, C3, or EMP3 were co-cultured with T cells, and tumor cell viability along with cytokine secretion profiles were analyzed. Knockdown of PLAUR or C3 significantly inhibited tumor cell viability (P < 0.0001, Fig. 7A), highlighting their roles in sustaining tumor cell survival. Analysis of cytokine secretion (Fig. 7B) revealed that knockdown of PLAUR, C3, or EMP3 significantly reduced levels of immunosuppressive cytokines, including TGF-β, IL-10, and IL-6 (P < 0.05). These cytokines are critical for suppressing T cell activity and facilitating immune escape, indicating that these genes contribute to creating an immunosuppressive tumor microenvironment. Conversely, PLAUR knockdown led to a marked increase in IFN-γ, IL-2, and TNF-α (P < 0.0001), suggesting enhanced T cell activation and inhibition of immune evasion. While C3 knockdown caused a modest increase in IL-2 and TNF-α (P < 0.0001), EMP3 knockdown primarily elevated TNF-α secretion (P < 0.0001), indicating its limited role in modulating pro-inflammatory cytokines. In conclusion, these findings demonstrate that PLAUR actively promotes immune evasion in ccRCC by enhancing the secretion of immunosuppressive cytokines while suppressing pro-inflammatory and T cell-activating cytokines. C3 plays a supportive but less pronounced role, and EMP3 exhibits minimal effects. Targeting PLAUR offers a promising strategy to disrupt immune evasion and restore T cell-mediated anti-tumor immunity in ccRCC. Fig. 7PLAUR, C3, and EMP3 were key drivers of immune evasion in ccRCC. (A) Tumor cell viability was evaluated using the CCK-8 assay in Caki-1 cells co-cultured with T cells after gene knockdown. (B) Cytokine secretion profiles, including IFN-γ, IL-2, TNF-α, TGF-β, IL-10, and IL-6 were analyzed using ELISA in co-cultured supernatants. Data are presented as mean ± SD. Statistical significance is indicated as follows: **P < 0.01, ****P < 0.0001; ns = not significant. PLAUR, C3, and EMP3 were key drivers of immune evasion in ccRCC. (A) Tumor cell viability was evaluated using the CCK-8 assay in Caki-1 cells co-cultured with T cells after gene knockdown. (B) Cytokine secretion profiles, including IFN-γ, IL-2, TNF-α, TGF-β, IL-10, and IL-6 were analyzed using ELISA in co-cultured supernatants. Data are presented as mean ± SD. Statistical significance is indicated as follows: **P < 0.01, ****P < 0.0001; ns = not significant. Discussion ccRCC remains a formidable challenge in oncology, characterized by its distinct genetic landscape [31], immune-rich TME [3], and inherent resistance to conventional therapies [18]. This study integrates bioinformatics with experimental validation to identify PLAUR, C3, and EMP3 as critical drivers of ccRCC progression and immune evasion. By elucidating their roles in ccRCC progression and immune modulation, this work provides mechanistic insights and potential therapeutic avenues for ccRCC. Bioinformatics analysis identified the upregulation of PLAUR, C3, and EMP3 in ccRCC samples compared to normal tissues. Experimental validation confirmed the significant overexpression of these genes in ccRCC cell lines at both the RNA and protein levels. Additionally, functional assays demonstrated that knockdown of PLAUR, C3, and EMP3 significantly inhibited tumor cell proliferation, migration, and invasion, with PLAUR exerting the most pronounced effects. Our single-cell analysis further clarified the cellular sources of these hub genes, indicating that PLAUR and C3 are predominantly expressed in immune cell populations, whereas EMP3 is broadly distributed and detectable in tumor cells. This heterogeneity underscores the multifaceted roles of these genes in both tumor-intrinsic and immune-mediated mechanisms of ccRCC progression. PLAUR, encoding the urokinase plasminogen activator receptor, facilitates ECM degradation through proteolytic cascades, thereby promoting tumor cell dissemination and the establishment of metastatic niches [30]. Its consistent overexpression in ccRCC and strong correlation with poor survival outcomes underscore its role as a pivotal driver of tumor progression [35, 36]. Mechanistically, PLAUR has been shown to advance ccRCC progression via promoting the PI3K/AKT/mTOR signaling pathway [24]. Similarly, C3, a pivotal component of the complement cascade, exhibits dual functions in stromal activation and immune regulation, contributing to angiogenesis and tumor cell survival [27]. The upregulation of C3 in ccRCC has been strongly linked to tumor progression and adverse prognosis [4, 26]. Although less extensively studied, EMP3 has been implicated in epithelial-mesenchymal transition (EMT) and the regulation of cell adhesion, suggesting a potential role in facilitating ccRCC metastasis [17]. ECM remodeling plays a pivotal role in ccRCC progression, facilitating tumor invasion and metastasis while modulating immune cell infiltration [22]. GO and KEGG analyses revealed that PLAUR, C3, and EMP3 are functionally enriched related to ECM dynamics, protein modification, and extracellular region functions, underscoring their critical roles in shaping the TME. These findings align with prior studies demonstrating that PLAUR regulates ECM turnover and cell adhesion through the activation of proteolytic cascades involving plasminogen activators and matrix metalloproteinases [7]. The moderate effects observed with C3 knockdown may reflect its involvement in complement-mediated regulation of the TME, including interactions with stromal fibroblasts and immune cells, which support angiogenesis and immune evasion [12]. In contrast, the limited impact of EMP3 knockdown on proliferation and migration suggests its role as an accessory factor, potentially contributing to ECM and TME modulation in synergy with other signaling pathways [35, 38]. Together, these findings highlight the diverse yet interconnected roles of PLAUR, C3, and EMP3 in driving ccRCC progression through ECM and TME regulation. ccRCC is characterized by its robust immune-evasive properties, largely driven by an immunosuppressive TME [9]. Our findings identify PLAUR as a key mediator of immune suppression, promoting the secretion of TGF-β, IL-10, and IL-6, which are well-established inhibitors of T cell activation and critical enablers of a suppressive TME conducive to tumor progression [8, 34]. Notably, PLAUR knockdown significantly shifted the cytokine profile, increasing the production of pro-inflammatory cytokines, thereby reactivating anti-tumor immune responses [19, 20]. While TNF-α exhibits dual roles in tumor progression, elevated levels are predominantly associated with anti-tumor effects [1]. These results position PLAUR as a central driver of immune evasion in ccRCC and a promising therapeutic target to restore immune surveillance. C3 further supports immune evasion through its activation fragments, C3a and C3b, which recruit MDSCs and impair cytotoxic T cell function [27]. C3 knockdown resulted in modest increases in pro-inflammatory cytokines, underscoring its contributory yet secondary role in immune suppression. EMP3 knockdown primarily increased TNF-α levels, suggesting a more limited role in immune modulation. Previous hypotheses linking EMP3 to immune evasion [17] are supported by our findings, which demonstrate its involvement but highlight its relatively minor impact compared to PLAUR and C3. Collectively, these findings elucidate the differential roles of PLAUR, C3, and EMP3 in shaping the immunosuppressive TME of ccRCC, offering insights into potential therapeutic strategies targeting these pathways. Emerging evidence further supports that the activation of specific metabolic pathways contributes to angiogenesis and inflammatory signatures in ccRCC [16, 21]. In addition, the unique features of the ccRCC TME, including its profound immune infiltration and stromal activation, substantially affect disease biology and influence responses to systemic therapy [5, 10, 12]. Recent studies have also emphasized the role of the complement system in modulating immune cell infiltration and immunoflogosis in ccRCC [11, 13, 15]. Within this broader context, our findings highlight PLAUR, C3, and EMP3 as key contributors linking extracellular matrix remodeling, immune modulation, and complement activation, thereby reinforcing their mechanistic relevance to the immunosuppressive and angiogenic landscape of ccRCC. Despite these strengths, several limitations should be acknowledged. Given that PLAUR and C3 are mainly derived from immune cells, our functional assays in tumor cell lines primarily address their tumor-intrinsic contributions, and additional studies in immune cell models will be required. While this study integrates bioinformatics and experimental data, the studies in vitro models may not capture the complexity of the TME. Validation in preclinical animal models and clinical samples will be essential to confirm the therapeutic relevance of PLAUR, C3, and EMP3. Additionally, the interplay between ECM remodeling, immune modulation, and metabolic reprogramming in ccRCC warrants further exploration to develop comprehensive treatment strategies. Conclusion This study identifies PLAUR, C3, and EMP3 as key regulators of ccRCC progression, driving tumor proliferation, invasion, and immune evasion. Among these, PLAUR emerges as the dominant driver, offering a compelling target for therapeutic intervention. By disrupting immune regulatory pathways, targeting these genes could enhance anti-tumor immunity and improve clinical outcomes in ccRCC patients. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1